[go: up one dir, main page]

WO2002003998A3 - Macrolide formulations for inhalation and methods of treatment of endobronchial infections - Google Patents

Macrolide formulations for inhalation and methods of treatment of endobronchial infections Download PDF

Info

Publication number
WO2002003998A3
WO2002003998A3 PCT/US2001/041328 US0141328W WO0203998A3 WO 2002003998 A3 WO2002003998 A3 WO 2002003998A3 US 0141328 W US0141328 W US 0141328W WO 0203998 A3 WO0203998 A3 WO 0203998A3
Authority
WO
WIPO (PCT)
Prior art keywords
erythromycylamine
formulation
treatment
methods
macrolide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/041328
Other languages
French (fr)
Other versions
WO2002003998A2 (en
Inventor
William R Baker
Peter B Challoner
Ribhi M Shawar
Kay K Huh
David M Rycman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ523693A priority Critical patent/NZ523693A/en
Priority to BR0112330-0A priority patent/BR0112330A/en
Priority to KR10-2003-7000412A priority patent/KR20030020924A/en
Priority to AU2001283491A priority patent/AU2001283491B2/en
Priority to EP01962298A priority patent/EP1309332A2/en
Priority to IL15387501A priority patent/IL153875A0/en
Priority to JP2002508452A priority patent/JP2004502736A/en
Priority to CA002415498A priority patent/CA2415498A1/en
Priority to US10/333,948 priority patent/US20040022740A1/en
Priority to AU8349101A priority patent/AU8349101A/en
Priority to MXPA03000321A priority patent/MXPA03000321A/en
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of WO2002003998A2 publication Critical patent/WO2002003998A2/en
Publication of WO2002003998A3 publication Critical patent/WO2002003998A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Macrolide formulations, such as an erythromycylamine formulation, for delivery by aerosolization are described. The concentrated erythromycylamine formulations contain an amount of erythromycylamine effective to treat infections caused by susceptible bacteria. Unit dose devices having a container containing a formulation of the macrolide antibiotic in a physiologically acceptable carrier are also described. Methods for treatment of pulmonary infections by a formulation (liquid solution, suspension, or dry powder) delivered as an aerosol having mass median aerodynamic diameter predominantly between 1 to 5 νm are also described.
PCT/US2001/041328 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections Ceased WO2002003998A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
NZ523693A NZ523693A (en) 2000-07-10 2001-07-01 Macrolide formulations for inhalation and methods of treatment of endobronchial infections
CA002415498A CA2415498A1 (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections
AU2001283491A AU2001283491B2 (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections
EP01962298A EP1309332A2 (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections
IL15387501A IL153875A0 (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections
JP2002508452A JP2004502736A (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treating endobronchial infections
AU8349101A AU8349101A (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections
BR0112330-0A BR0112330A (en) 2000-07-10 2001-07-10 Inhalation macrolides formulations and their uses for the treatment of endobronchial infections
US10/333,948 US20040022740A1 (en) 2001-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections
MXPA03000321A MXPA03000321A (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections.
KR10-2003-7000412A KR20030020924A (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21703200P 2000-07-10 2000-07-10
US60/217,032 2000-07-10

Publications (2)

Publication Number Publication Date
WO2002003998A2 WO2002003998A2 (en) 2002-01-17
WO2002003998A3 true WO2002003998A3 (en) 2002-06-13

Family

ID=22809403

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/041328 Ceased WO2002003998A2 (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections

Country Status (11)

Country Link
EP (1) EP1309332A2 (en)
JP (1) JP2004502736A (en)
KR (1) KR20030020924A (en)
CN (1) CN1202831C (en)
AU (2) AU8349101A (en)
BR (1) BR0112330A (en)
CA (1) CA2415498A1 (en)
IL (1) IL153875A0 (en)
MX (1) MXPA03000321A (en)
NZ (1) NZ523693A (en)
WO (1) WO2002003998A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1487413A4 (en) * 2002-03-05 2010-11-10 Transave Inc An inhalation system for prevention and treatment of intracellular infections
AU2003205499A1 (en) * 2003-02-28 2004-09-17 Anbics Patents-Licences Ag Method for treatment and prevention of acute and chronic pseudomonas aeruginosa airway infections with inhalable macrolides
ES2552682T3 (en) 2003-03-10 2015-12-01 Merck Sharp & Dohme Corp. Novel antibacterial agents
MXPA05013324A (en) * 2003-06-10 2006-03-09 Astellas Pharma Inc AEROSOL PREPARATION UNDERSTANDING AN ANNEX THAT INCLUDES A COMPOSITION OF AEROSOL CONTAINING MACROLID COMPOUND.
US20050266578A1 (en) * 2004-05-06 2005-12-01 Gruenke Larry D Methods and systems for detection of macrolides
ES2358024T3 (en) 2004-05-17 2011-05-04 Gilead Sciences, Inc. AEROSOLIZED PHOSPHOMYCIN / AMINOGLUCOSIDE COMBINATION FOR THE TREATMENT OF BACTERIAL RESPIRATORY INFECTIONS.
EP2083833B1 (en) * 2006-10-11 2018-01-24 Laboratoires SMB SA Pharmaceutical anti-infective composition for inhalation.
EP2030644A1 (en) 2007-08-31 2009-03-04 PARI Pharma GmbH Aerosols for sinunasal drug delivery
AU2008316830B2 (en) 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
EP2098219A1 (en) * 2008-03-05 2009-09-09 PARI Pharma GmbH Macrolide compositions having improved taste and stability
AU2009308181B2 (en) 2008-10-24 2015-12-03 Cempra Pharmaceuticals, Inc. Methods for treating resistant diseases using triazole containing macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
WO2011112864A1 (en) * 2010-03-10 2011-09-15 Cempra Pharmaceuticals, Inc. Parenteral formulations of macrolide antibiotics
SI2571506T1 (en) 2010-05-20 2017-12-29 Cempra Pharmaceuticals, Inc. Processes for preparing macrolides and ketolides and intermediates therefor
US9815863B2 (en) 2010-09-10 2017-11-14 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
SG11201405895UA (en) 2012-03-27 2014-10-30 Cempra Pharmaceuticals Inc Parenteral formulations for administering macrolide antibiotics
CN105163785A (en) 2013-03-14 2015-12-16 森普拉制药公司 Methods for treating respiratory diseases and formulations therefor
JP6675973B2 (en) 2013-03-15 2020-04-08 センプラ ファーマシューティカルズ，インコーポレイテッド Focused method for preparing macrolide antimicrobial agents
FI20205368A1 (en) * 2020-04-07 2021-10-08 Aalto Univ Foundation Sr Formulation
CN114796116A (en) * 2022-05-17 2022-07-29 中山大学附属第六医院 Azithromycin inhalant and preparation method thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006775A1 (en) * 1988-12-14 1990-06-28 Liposome Technology, Inc. A novel nonphospholipid liposome composition for sustained release of drugs
WO1995015182A1 (en) * 1993-12-02 1995-06-08 Emory University Antiinfective compositions and methods of use
WO1995025510A1 (en) * 1994-03-18 1995-09-28 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pharmaceutical compositions containing alkylthioalkanoic acids or derivatives thereof and their use in the treatment of mycobacterial infections and as antiseptic
EP0700678A1 (en) * 1994-07-13 1996-03-13 Wakamoto Pharmaceutical Co., Ltd. Stable lipid emulsion
WO1996037190A1 (en) * 1995-05-23 1996-11-28 Boehringer Ingelheim Vetmedica Gmbh Stable, concentrated, locally-tolerated erythromycylamine solutions
WO2000015207A2 (en) * 1998-09-15 2000-03-23 Naeja Pharmaceutical Inc. Combination for the treatment of inflammation using elastine inhibitor(s) and antibacterial agent(s)
WO2000035408A2 (en) * 1998-12-18 2000-06-22 Pathogenesis Corporation Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
US6156294A (en) * 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60209517A (en) * 1984-04-03 1985-10-22 Unitika Ltd Aerosol composition
IE63869B1 (en) * 1986-11-06 1995-06-14 Res Dev Foundation Aerosols containing liposomes and method for their preparation
JPH01283225A (en) * 1988-05-10 1989-11-14 Toyo Jozo Co Ltd Aerosol preparation for treating infectious disease of bovine respiratory organ and treating method using the same
ES2205560T5 (en) * 1997-09-29 2013-04-16 Novartis Ag Stabilized preparations for use in metered dose inhalers
WO2000012116A1 (en) * 1998-08-28 2000-03-09 Eli Lilly And Company Method for administering insulinotropic peptides
IT1303692B1 (en) * 1998-11-03 2001-02-23 Chiesi Farma Spa PROCEDURE FOR THE PREPARATION OF SUSPENSIONS OF PARTICLES OF DRUGS TO BE ADMINISTERED BY INHALATION.
EP1161247A4 (en) * 1998-12-17 2002-05-15 Chiron Corp Method for the treatment of severe chronic bronchitis (bronchiectasis) with an aerosolized antibiotic

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006775A1 (en) * 1988-12-14 1990-06-28 Liposome Technology, Inc. A novel nonphospholipid liposome composition for sustained release of drugs
WO1995015182A1 (en) * 1993-12-02 1995-06-08 Emory University Antiinfective compositions and methods of use
WO1995025510A1 (en) * 1994-03-18 1995-09-28 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pharmaceutical compositions containing alkylthioalkanoic acids or derivatives thereof and their use in the treatment of mycobacterial infections and as antiseptic
EP0700678A1 (en) * 1994-07-13 1996-03-13 Wakamoto Pharmaceutical Co., Ltd. Stable lipid emulsion
WO1996037190A1 (en) * 1995-05-23 1996-11-28 Boehringer Ingelheim Vetmedica Gmbh Stable, concentrated, locally-tolerated erythromycylamine solutions
WO2000015207A2 (en) * 1998-09-15 2000-03-23 Naeja Pharmaceutical Inc. Combination for the treatment of inflammation using elastine inhibitor(s) and antibacterial agent(s)
WO2000035408A2 (en) * 1998-12-18 2000-06-22 Pathogenesis Corporation Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
US6156294A (en) * 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media

Also Published As

Publication number Publication date
MXPA03000321A (en) 2003-06-06
WO2002003998A2 (en) 2002-01-17
EP1309332A2 (en) 2003-05-14
CA2415498A1 (en) 2002-01-17
JP2004502736A (en) 2004-01-29
AU2001283491B2 (en) 2007-02-15
KR20030020924A (en) 2003-03-10
BR0112330A (en) 2003-10-07
CN1202831C (en) 2005-05-25
IL153875A0 (en) 2003-07-31
CN1471401A (en) 2004-01-28
NZ523693A (en) 2004-08-27
AU8349101A (en) 2002-01-21

Similar Documents

Publication Publication Date Title
WO2002003998A3 (en) Macrolide formulations for inhalation and methods of treatment of endobronchial infections
DE60210402D1 (en) System for delivering a tobramycin formulation
GR3031770T3 (en) Novel and improved aminoglycoside formulation for aerosolization
CA2369722A1 (en) Powder inhaler for combined medicament
MY121789A (en) Closure-cap and container as a two-chamber cartridge for nebulisers for producing aerosols and active substance formulations, suitable for storage
WO2001049274A3 (en) Methods for pulmonary delivery of interleukin-2
CA2049302A1 (en) Aerosol carriers
PL317225A1 (en) Drugs
IL149085A0 (en) A dry powder composition containing a di or tripeptide
WO2007067520A3 (en) Lipid-based compositions of antiinfectives for treating pulmonary infections
CA2322434A1 (en) Medicament delivery and packaging
CA2277913A1 (en) New formulation for inhalation having a poured bulk density of 0.28 to 0.38 g/ml, a process for preparing the formulation and the use thereof
YU56600A (en) Device for delivering an active agent to the lung of a human patient
CA2136740A1 (en) Arrangement and method for dispensing preservative-free nasal sprays and similar preparations
WO2000021594A3 (en) Flow resistance modulated aerosolized active agent delivery
WO2002043750A3 (en) Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations
CA2445516A1 (en) Metered dose delivery device for liquid and powder agents
HK1042234A1 (en) Pulmonary administration of dry powder formulations for treating infertility
CA2564546A1 (en) Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections
WO2002024261A3 (en) Shock wave aerosolization apparatus and method
WO2005037256A3 (en) Liquid preparation containing tobramycin
CA2348024A1 (en) Granular, free-flowing pharmaceutical composition, and straw-like dosage form for oral administration thereof
AU2003215588A1 (en) Aerosol formulations containing esters of 3,17-dihydroxy oestratriene derivatives for pulmonary delivery

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 153875

Country of ref document: IL

Ref document number: 2415498

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020037000412

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2001283491

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 523693

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001962298

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 018141218

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020037000412

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001962298

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2003115433

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 10333948

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 523693

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 523693

Country of ref document: NZ